Normal Fasting Plasma Glucose Levels and Type 2 Diabetes in Young Men
Amir Tirosh, M.D., Ph.D., Iris Shai, R.D., Ph.D., Dorit Tekes-Manova, M.D., Eran Israeli, M.D., David Pereg, M.D., Tzippora Shochat, M.Sc., Ilan Kochba, M.D., Assaf Rudich, M.D., Ph.D., for the Israeli Diabetes Research Group
Background The normal fasting plasma glucose level was recentlydefined as less than 100 mg per deciliter (5.55 mmol per liter).Whether higher fasting plasma glucose levels within this rangeindependently predict type 2 diabetes in young adults is unclear.
Methods We obtained blood measurements, data from physical examinations,and medical and lifestyle information from men in the IsraelDefense Forces who were 26 to 45 years of age.
Results A total of 208 incident cases of type 2 diabetes occurredduring 74,309 person-years of follow-up (from 1992 through 2004)among 13,163 subjects who had baseline fasting plasma glucoselevels of less than 100 mg per deciliter. A multivariate model,adjusted for age, family history of diabetes, body-mass index,physical-activity level, smoking status, and serum triglyceridelevels, revealed a progressively increased risk of type 2 diabetesin men with fasting plasma glucose levels of 87 mg per deciliter(4.83 mmol per liter) or more, as compared with those whoselevels were in the bottom quintile (less than 81 mg per deciliter[4.5 mmol per liter], P for trend <0.001). In multivariatemodels, men with serum triglyceride levels of 150 mg per deciliter(1.69 mmol per liter) or more, combined with fasting plasmaglucose levels of 91 to 99 mg per deciliter (5.05 to 5.50 mmolper liter), had a hazard ratio of 8.23 (95 percent confidenceinterval, 3.6 to 19.0) for diabetes, as compared with men witha combined triglyceride level of less than 150 mg per deciliterand fasting glucose levels of less than 86 mg per deciliter(4.77 mmol per liter). The joint effect of a body-mass index(the weight in kilograms divided by the square of the heightin meters) of 30 or more and a fasting plasma glucose levelof 91 to 99 mg per deciliter resulted in a hazard ratio of 8.29(95 percent confidence interval, 3.8 to 17.8), as compared witha body-mass index of less than 25 and a fasting plasma glucoselevel of less than 86 mg per deciliter.
Conclusions Higher fasting plasma glucose levels within thenormoglycemic range constitute an independent risk factor fortype 2 diabetes among young men, and such levels may help, alongwith body-mass index and triglyceride levels, to identify apparentlyhealthy men at increased risk for diabetes.
The definition of a normal fasting plasma glucose level hasrecently been revised by the Expert Committee on the Diagnosisand Classification of Diabetes Mellitus of the American DiabetesAssociation. An impaired fasting plasma glucose level is nowconsidered to include the range of 100 to 109 mg per deciliter(5.55 to 6.05 mmol per liter).1 Although it raises considerablecontroversy regarding the implications for health care policy,2,3,4,5,6the concept that persons with fasting plasma glucose levelsof 100 to 109 mg per deciliter are at increased risk for thedevelopment of type 2 diabetes, as compared with those withfasting plasma glucose levels of less than 100 mg per deciliter,is substantiated by data.5,7,8 Nonetheless, the question ofwhether there is an association between elevated fasting plasmaglucose levels within the newly defined normal range and anincreased risk of diabetes, and whether this association actsas an independent risk factor for the disease, has not beenanswered. This issue is particularly important for young adults,in whom the association between fasting plasma glucose levelsand diabetes may have been masked in earlier studies that analyzedpopulations with a wide age range.8,9 In young adults, the absoluteincidence of type 2 diabetes is low, but a marked surge in diabetes-associatedmorbidity has recently been reported.10 Better and earlier identificationof young adults at risk for the development of diabetes maybe warranted, given the success of interventions aimed at delayingthe onset of diabetes among high-risk groups.11,12,13,14,15
Our investigation, which involved the use of data from the Metabolic,Lifestyle, and Nutrition Assessment in Young Adults (MELANY)study, assessed whether fasting plasma glucose levels can helpto identify young, healthy, normoglycemic persons at increasedrisk for type 2 diabetes.
Methods
The Melany Study
The MELANY study has been conducted at the Israel Defense ForcesStaff Periodic Examination Center, to which all career servicepersonnel older than 25 years of age are referred every threeto five years. A computerized database established in 1992 isthe source of data for MELANY, which was designed to investigaterisk factors for common diseases in young adults. At each visitto the Staff Periodic Examination Center, participants completeda detailed questionnaire assessing demographic, nutritional,lifestyle, and medical factors. Thereafter, blood samples weredrawn after a 14-hour fast and analyzed. A trained medical technicianmeasured height and weight, and a physician at the center performeda complete physical examination. Primary care for all IsraelDefense Forces personnel between scheduled visits to the centeris obtained at designated military clinics, and all medicalinformation was recorded in the same central database, therebyfacilitating ongoing, tight, and uniform follow-up.
The institutional review board of the Israel Defense ForcesMedical Corps approved this study on the basis of strict maintenanceof participants' anonymity during database analyses. Data fromsubjects were recorded anonymously, and no individual consentwas obtained. The authors are solely responsible for the designof the study, analysis and interpretation of the data, and writingof the manuscript, without any form of censorship or limitationby the Israel Defense Forces.
Inclusion and Exclusion Criteria
Included in the study have been 13,163 men with fasting plasmaglucose levels of less than 100 mg per deciliter at their initialStaff Periodic Examination Center visit, for whom follow-updata have been available through either a subsequent scheduledvisit or visits (average number of visits per person, 2.5; range,2 to 6) or from the primary physician for men who have receiveda diagnosis of diabetes. The ongoing cohort of the MELANY studycurrently includes 9538 additional men for whom follow-up dataare not yet available. Patients were excluded from the studyif they had confirmed type 1 or type 2 diabetes at the timeof enrollment. Women were not included, since only 11 new casesof diabetes were diagnosed among 1961 normoglycemic women, aninsufficient number of incident cases to facilitate meaningfulanalysis. Glucose-tolerance tests, shown rarely to be impairedin people with fasting glucose levels of less than 100 mg perdeciliter,16 were not performed, a decision consistent withcurrent clinical guidelines for the diagnosis of diabetes inyoung, asymptomatic, normoglycemic persons.17
Outcome Definitions
The diagnosis of type 2 diabetes was defined as the primaryend point of the study. All cases of diabetes were diagnosedaccording to the criteria published by the American DiabetesAssociation expert committee.18 The diagnoses of all 208 newcases of diabetes in the MELANY study were made on the basisof two fasting plasma glucose levels of 126 mg per deciliter(7.00 mmol per liter) or more. Since the diagnostic criteriafor diabetes were changed during the follow-up period, all fastingglucose values were revised to identify subjects with fastingplasma glucose levels of 126 to 140 mg per deciliter (7.00 to7.77 mmol per liter). Of the 208 subjects with diabetes, 26received a diagnosis before July 1997, and three cases weredetected when the new diagnostic criteria were applied to thepopulation already enrolled in the study at that time. Duringthe follow-up period, two patients received a diagnosis of type1 diabetes and were excluded from the study. An end-point determinationwas made at each sequential Staff Periodic Examination Centervisit according to measurements of fasting plasma glucose. Alternatively,between visits, the diagnosis of diabetes was made by the IsraelDefense Forces primary care physician on the basis of the samediagnostic criteria described above.18 Three army physiciansreviewed and confirmed each of the cases before recording themin the central medical corps database.
Laboratory Methods
Biochemical analyses of blood were performed on fresh samplesin a core laboratory facility that handles 1.2 million samplesper year. The laboratory is authorized to perform tests accordingto the international quality standard ISO-9002. Periodic assessmentof quality control (by the British company National ExternalQuality Assessment Service) has been performed on a regularbasis. To ensure that venous fasting plasma glucose levels werereliably determined, blood samples were collected in tubes containingsodium fluoride and delivered to the laboratory within two hours.All measured biochemical markers were identified with the useof a BM/Hitachi917 automated analyzer (Boehringer Mannheim).Blood pressure measurements were performed by medical technicianswith the use of mercury sphygmomanometers.
Statistical Analysis
We excluded 3784 of the 16,947 young men at enrollment, 403because of preexisting diabetes and 3381 because of impairedfasting plasma glucose levels (100 mg per deciliter or more).For analysis, we included 13,163 normoglycemic men with baselinefasting glucose levels of less than 100 mg per deciliter. Ageneral linear model was used to assess the age-adjusted meansand proportions of the population's characteristics across quintilesof fasting glucose levels and to fit the median of the quintilesas a continuous variable to estimate the trend of variablesacross quintiles. We conducted a Cox proportional-hazards analysisduring each interval of follow-up to estimate the hazard ratiosand 95 percent confidence intervals for the development of type2 diabetes. We added the values for body-mass index (the weightin kilograms divided by the square of the height in meters)and triglyceride levels separately to the age-adjusted modelto evaluate the potential role of each as a confounder of thetested association between fasting plasma glucose level anddiabetes. In the final multivariate model, we controlled forage, family history of diabetes, body-mass index, serum triglyceridelevels, physical-activity level, and smoking status. We testedfor effect modification with stratified analyses of body-massindex, triglyceride levels, and family history of diabetes,all of which remained independent risk factors for diabetesin the multivariate model. Interaction terms were computed bymodeling the quintile medians as continuous variables. Next,we evaluated the joint risk attributed to fasting plasma glucoselevels (categorized according to the bottom two quintiles, themedian quintile, and the top two quintiles) with either body-massindex (<25, 25 to 29.9, and 30) or with triglyceride levels(<150 or 150 mg per deciliter [1.69 mmol per liter]). Wecalculated the population attributable risk as previously described.19All statistical analyses were performed with the use of SASstatistical software, version 8.0.
Results
Data from 13,163 apparently healthy men (mean age, 32 years;range, 26 to 45) with fasting plasma glucose levels of lessthan 100 mg per deciliter at baseline were analyzed. Age-adjustedvalues for body-mass index, triglyceride levels, and the proportionof men with a family history of diabetes were more likely toincrease across quintiles of fasting glucose levels (Table 1).
Table 1. Age-Adjusted Baseline Characteristics of 13,163 Men According to Quintiles of Normal Fasting Plasma Glucose Levels.
During 74,309 person-years (mean follow-up, 5.7 years), therewere 208 documented incident cases of type 2 diabetes. Age-adjustedhazard ratios for type 2 diabetes increased across quintilesof fasting plasma glucose levels, reaching 3.05 (95 percentconfidence interval, 1.78 to 5.18) for the top quintile as comparedwith the bottom quintile (P for trend <0.001) (Table 2).Further adjustments for body-mass index and triglyceride levelsonly mildly attenuated the risk values. In a multivariate modeladjusted for age, family history of diabetes, body-mass index,serum triglyceride levels, physical activity, and smoking status,we observed a significant and progressive increase in the riskof diabetes in men with fasting plasma glucose levels in thethird, fourth, and fifth quintiles as compared with the bottomquintile (P for trend <0.001) (Table 2). This associationremained unchanged after further adjustment for blood pressureand for the ratio of total cholesterol to high-density lipoprotein(HDL) cholesterol, as well as after a secondary analysis thatexcluded 27 subjects who had received a diagnosis of diabeteswithin the first two years of follow-up (data not shown).
Table 2. Hazard Ratios for Type 2 Diabetes among 13,163 Men According to Quintiles of Normal Fasting Plasma Glucose Levels.
The addition of fasting plasma glucose levels to a model adjustedfor age, body-mass index, family history of diabetes, smokingstatus, the presence or absence of hypertension, physical-activitylevel, triglyceride levels, and ratio of total cholesterol toHDL cholesterol further improved the prediction model (P<0.001on the basis of the likelihood-ratio test).
In the multivariate model, serum triglyceride levels and familyhistory of diabetes, in addition to fasting plasma glucose levelsand body-mass index, remained independent risk factors for thedevelopment of diabetes (data not shown). Thus, we further assessedthe association between fasting plasma glucose levels and theoccurrence of type 2 diabetes among strata of these independentrisk factors (Table 3). In the multivariate models, increasedlevels of normal fasting plasma glucose were more strongly associatedwith diabetes among overweight and obese men (those with a body-massindex of 25 or more) than among leaner men (P for interaction,0.03). The trend of increased risk of type 2 diabetes acrossincreasing quintiles of normal fasting plasma glucose levelsappeared to be similar among subgroups classified accordingto triglyceride levels and family-history status (P for interaction>0.05).
Table 3. Stratified Analysis of Multivariate Hazard Ratios for Type 2 Diabetes among 13,163 Men According to Quintiles of Normal Fasting Glucose Plasma.
We assessed the joint effect of fasting plasma glucose levelsand either triglyceride levels or body-mass index on the riskof type 2 diabetes. In multivariate models, serum triglyceridelevels of 150 mg per deciliter or more were associated withan increased risk of diabetes in each category of fasting plasmaglucose levels, as compared with the risk in the respectivelow-serum-triglyceride group (Figure 1A). Men with fasting plasmaglucose levels at the high end of the normal range (91 to 99mg per deciliter [5.05 to 5.50 mmol per liter]) and serum triglyceridelevels of 150 mg per deciliter or more had a risk of 8.23 (95percent confidence interval, 3.6 to 19.0) for the developmentof diabetes, as compared with those with fasting glucose levelsof 86 mg per deciliter (4.77 mmol per liter) or less and triglyceridelevels of less than 150 mg per deciliter. When we cross-classifiedbody-mass index with fasting plasma glucose levels, we observedthat each risk factor enhanced the association of the otherfactor with type 2 diabetes (Figure 1B). Obese men (those witha body-mass index of 30 or more) with fasting plasma glucoselevels in the high-normal range had a hazard ratio of 8.29 (95percent confidence interval, 3.8 to 17.8) for the developmentof diabetes, as compared with the reference group, whereas thosewith fasting plasma glucose levels between 87 and 90 mg perdeciliter had a risk of 7.78 (95 percent confidence interval,3.2 to 18.7). The joint effect of obesity and fasting plasmaglucose levels was also apparent in the population attributablerisk. Among lean men, 27.5 percent of cases of diabetes couldbe prevented by modifying the risk attributable to elevatedfasting plasma glucose levels, and in men with the lowest rangeof fasting plasma glucose levels, 29.1 percent of cases couldbe attributed to obesity. The combined, population attributablerisk increased to 60.5 percent among men with the highest valuesfor both body-mass index and fasting plasma glucose levels,as compared with the reference group.
Figure 1. Joint Effect of Fasting Plasma Glucose Levels, Triglyceride Levels, and Body-Mass Index in Predicting Type 2 Diabetes among 13,163 Men.
Panel A shows the hazard ratios for diabetes according to fasting plasma glucose and triglyceride levels. The number of new cases of diabetes that were detected in each of the fasting plasma glucose groups, according to the two triglyceride levels (<150 and 150 mg per deciliter, respectively), are as follows: a fasting plasma glucose level of 86 mg per deciliter or less, 20 of 3821 subjects and 30 of 1595; a level of 87 to 90 mg per deciliter, 37 of 2779 and 20 of 592; and a level of 91 to 99 mg per deciliter, 40 of 2997 and 61 of 1379. Panel B shows the relative risk according to body-mass index. The number of new cases of diabetes detected in each group according to body-mass index (less than 25 [lean], 25 to 29.9 [overweight], or higher than 30 [obese]), respectively, were as follows:a fasting plasma glucose level of 86 mg per deciliter or less, 11 of 2511 subjects, 23 of 2057, and 13 of 506; a level of 87 to 90 mg per deciliter, 5 of 1177, 18 of 1129, and 17 of 292; and a level of 91 to 99 mg per deciliter, 19 of 2292, 64 of 2528, and 38 of 671. The multivariate model was adjusted, if not stratified, for age, body-mass index, and triglyceride levels as continuous variables; physical activity (60 or >60 minutes per week or missing information); family history of diabetes (positive, negative, or missing information); and smoking status (current smoker, non-current smoker, or missing information). CI denotes confidence interval.
Discussion
In this follow-up study of 13,163 apparently healthy young adultmen, we found an increased risk of type 2 diabetes across quintilesof fasting plasma glucose levels within the newly defined normalrange; this increase was independent of other traditional riskfactors for diabetes. Our findings suggest that among youngadults, who generally have a relatively low incidence of diabetes,elevated normal fasting plasma glucose levels may predict type2 diabetes.
Several limitations of this study warrant consideration. First,the MELANY cohort may be considered representative of a uniquegroup of healthy young men. However, the characteristics ofthe population are strikingly similar to those of cohorts inpublished studies of young men from various industrialized countries,20,21,22,23,24and the relatively homogeneous environment to which participantsin our study were exposed might reduce the effect of unknownconfounders. Second, although they did not compromise the outcomedefinition, measurements of circulating insulin, C-peptide,or both were not obtained in this study, limiting our abilityto assess the role of insulin resistance in the associationbetween normal fasting plasma glucose levels and diabetes. Finally,we did not measure glycosylated hemoglobin levels or performglucose-tolerance tests. Although the current definition ofnormal fasting plasma glucose levels resulted in a substantialincrease in the overlap with normal glucose tolerance, as definedby glucose-tolerance testing,8 we may have missed men with normalfasting plasma glucose levels who were already glucose intolerantat enrollment. To limit this possibility, we confirmed our resultsby performing a secondary analysis in which a two-year lag betweenenrollment and outcome was used. The strengths of the MELANYstudy include the detailed, uniform, and systematic follow-upand outcome definition; the use of measured (rather than reported)values for the body-mass index; the availability of reliabledeterminations of glucose levels in fresh venous blood; andthe direct measurements of lipids.
The identification of a high-normal fasting plasma glucose levelas a risk factor for type 2 diabetes may help to identify young,healthy men for whom preventive interventions might be considered.Indeed, a number of strategies, including lifestyle modification14and medications such as metformin,14 thiazolidinediones,13 acarbose,11,12and orlistat15 have been reported as efficient interventionsthat may delay the onset of diabetes in selected groups thathave classic risk factors for the disease. If such strategiesare also found to be efficacious in preventing diabetes in youngmen with high-normal fasting plasma glucose levels, the findingsof our study may facilitate efforts to halt the diabetes pandemicthat is increasingly affecting people in the third to fifthdecades of life.10
An impaired fasting plasma glucose level is a known risk factorfor diabetes, along with other traditional risk factors suchas a family history, sedentary lifestyle, central adiposity,dyslipidemia, and hypertension.25 However, the definition ofa normal fasting plasma glucose level was recently revised tobe less than 100 mg per deciliter.2 It is interesting to notethat a few studies have reported the absence of a thresholdin the association between fasting plasma glucose levels andthe risk of diabetes in cohorts with a wide age range. Furthermore,a fasting plasma glucose level of 94 mg per deciliter (5.22mmol per liter) was suggested as an optimal point of specificityand sensitivity for predicting type 2 diabetes.8,9 Our resultssuggest that in young men, fasting plasma glucose levels withinthe normoglycemic range can predict type 2 diabetes. Consistentwith our findings is the observation that elevated fasting plasmaglucose levels within the normoglycemic range can predict cardiovascular,cerebrovascular, and overall mortality risks in persons 45 yearsof age or older.26,27 Thus, subcategories within the range definedas normal for fasting plasma glucose levels contain informationrelevant for the assessment of the risk of various diseases,28,29as indicated here for type 2 diabetes.
More than half of the entire study population had fasting plasmaglucose levels exceeding 90 mg per deciliter (5.00 mmol perliter), which were associated with a significantly increasedrisk of diabetes during the mean follow-up of nearly six years.The absolute incident risk of type 2 diabetes among men whohad fasting plasma glucose levels of 91 to 99 mg per deciliterwas 2.3 percent during this follow-up period. Therefore, designatinga fasting plasma glucose level of more than 90 mg per deciliteras the sole marker of imminent diabetes is unlikely to be useful.Alternatively, the use of an individualized definition of anormal fasting plasma glucose level, which incorporates thecompound effect observed with body-mass index and triglyceridelevels (Figure 1), may prove to be of greater clinical value.Indeed, among normoglycemic obese subjects with fasting plasmaglucose levels of more than 90 mg per deciliter, the incidenceof diabetes was 5.7 percent, as compared with 0.4 percent inlean men with glucose levels of 86 mg per deciliter or less.On the basis of population attributable risk, 60.5 percent ofthe cases might be preventable by a joint reduction in the risksassociated with obesity and high-normal fasting plasma glucoselevels. Risk stratification for the definition of normoglycemiais reminiscent of the current guidelines for antidyslipidemicand antihypertensive interventions.30
Our study raises potential testable hypotheses with regard tomechanisms. The fasting plasma glucose level is largely determinedby hepatic glucose production.31 Thus, the observation thata high-normal fasting plasma glucose level predicts type 2 diabetessuggests that a relative overproduction of hepatic glucose alreadyexists early in the natural history of diabetes and is exaggeratedby obesity (Figure 1B). Obese persons who do not have diabetesconsistently exhibit an enhanced rate of glucose production.32This enhanced rate may emanate from elevated levels of freefatty acids that directly accelerate the rate of hepatic gluconeogenesis,33combined with desensitization of the hepatic regulatory loopinvolving hypothalamic sensing of fatty acids.34 Obesity-associatedaltered secretion of adipocytokines from adipocytes, macrophagesin fat tissue, or both has been suggested as the mechanism involvedin mediating such dysregulated "crosstalk" between fatty tissueand the liver.35,36,37,38 Understanding the operative mechanismsthat regulate fasting plasma glucose levels may bring us closerto finding new and effective measures to prevent type 2 diabetesin young adults.
Supported by the Israel Defense Forces Medical Corps.
We are indebted to Drs. Ilana Harman-Boehm and Shimon Weitzmanof the Soroka Medical Center and Ben-Gurion University, Beer-Sheva,Israel, for their valuable discussions and careful reading ofthe manuscript; to Dr. Itamar Raz, Hadassah Medical Center,Jerusalem, for his support and encouragement; and to Ms. YehuditMish for her valuable assistance with data collection.
Source Information
From the Medical Corps Headquarters (A.T., E.I., T.S., I.K.) and the Center for Medical Services (D.T.-M.), Israel Defense Forces Medical Corps; the Department of Internal Medicine A, Sheba Medical Center, Tel-Hashomer (A.T.); the S. Daniel Abraham International Center for Health and Nutrition (I.S., A.R.), the Department of Epidemiology (I.S.), and the Department of Clinical Biochemistry (A.R.), Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva; and the Department of Internal Medicine A, Meir Hospital, Sapir Medical Center, Kfar-Sava (D.P.) all in Israel. Drs. Tirosh and Shai contributed equally to the study.
Address reprint requests to Dr. Tirosh at the Department of Internal Medicine A, Sheba Medical Center, Tel-Hashomer, Israel, or at amirt{at}bgumail.bgu.ac.il.
References
Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160-3167. [Free Full Text]
Genuth S. Lowering the criterion for impaired fasting glucose is in order. Diabetes Care 2003;26:3331-3332. [Free Full Text]
Borch-Johnsen K, Colagiuri S, Balkau B, et al. Creating a pandemic of prediabetes: the proposed new diagnostic criteria for impaired fasting glycaemia. Diabetologia 2004;47:1396-1402. [Web of Science][Medline]
Piche ME, Arcand-Bosse JF, Despres JP, Perusse L, Lemieux S, Weisnagel SJ. What is a normal glucose value? Differences in indexes of plasma glucose homeostasis in subjects with normal fasting glucose. Diabetes Care 2004;27:2470-2477. [Free Full Text]
Tai ES, Goh SY, Lee JJ, et al. Lowering the criterion for impaired fasting glucose: impact on disease prevalence and associated risk of diabetes and ischemic heart disease. Diabetes Care 2004;27:1728-1734. [Free Full Text]
Schriger DL, Lorber B. Lowering the cut point for impaired fasting glucose: where is the evidence? Where is the logic? Diabetes Care 2004;27:592-601. [Free Full Text]
Bortheiry AL, Malerbi DA, Franco LJ. The ROC curve in the evaluation of fasting capillary blood glucose as a screening test for diabetes and IGT. Diabetes Care 1994;17:1269-1272. [Abstract]
Gabir MM, Hanson RL, Dabelea D, et al. The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 2000;23:1108-1112. [Free Full Text]
Shaw JE, Zimmet PZ, Hodge AM, et al. Impaired fasting glucose: how low should it go? Diabetes Care 2000;23:34-39. [Abstract]
Bloomgarden ZT. Type 2 diabetes in the young: the evolving epidemic. Diabetes Care 2004;27:998-1010. [Free Full Text]
Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-2077. [CrossRef][Web of Science][Medline]
Chiasson JL, Josse RG, Gomis R, et al. Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data. Diabetologia 2004;47:969-975. [Medline]
Durbin RJ. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab 2004;6:280-285. [CrossRef][Medline]
Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403. [Free Full Text]
Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-161. [Erratum, Diabetes Care 2004;27:856.] [Free Full Text]
Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 2002;19:708-723. [CrossRef][Web of Science][Medline]
American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2004;27:Suppl 1:S11-S14.
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-1197. [Web of Science][Medline]
Rothman KJ, Greenland S. Modern epidemiology. 2nd ed. Philadelphia: Lippincott-Raven, 1998.
Juonala M, Viikari JS, Hutri-Kahonen N, et al. The 21-year follow-up of the Cardiovascular Risk in Young Finns Study: risk factor levels, secular trends and east-west difference. J Intern Med 2004;255:457-468. [CrossRef][Web of Science][Medline]
Urbina EM, Srinivasan SR, Kieltyka RL, et al. Correlates of carotid artery stiffness in young adults: the Bogalusa Heart Study. Atherosclerosis 2004;176:157-164. [CrossRef][Web of Science][Medline]
Stamler J, Stamler R, Neaton JD, et al. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. JAMA 1999;282:2012-2018. [Free Full Text]
Navas-Nacher EL, Colangelo L, Beam C, Greenland P. Risk factors for coronary heart disease in men 18 to 39 years of age. Ann Intern Med 2001;134:433-439. [Erratum, Ann Intern Med 2001;135:71.] [Free Full Text]
Diez Roux AV, Jacobs DR, Kiefe CI. Neighborhood characteristics and components of the insulin resistance syndrome in young adults: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Diabetes Care 2002;25:1976-1982. [Free Full Text]
Stern MP, Williams K, Haffner SM. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 2002;136:575-581. [Free Full Text]
Tanne D, Koren-Morag N, Goldbourt U. Fasting plasma glucose and risk of incident ischemic stroke or transient ischemic attacks: a prospective cohort study. Stroke 2004;35:2351-2355. [Free Full Text]
Simons LA, Friedlander Y, McCallum J, Simons J. Fasting plasma glucose in non-diabetic elderly women predicts increased all-causes mortality and coronary heart disease risk. Aust N Z J Med 2000;30:41-47. [Web of Science][Medline]
Thomas GN, Chook P, Qiao M, et al. Deleterious impact of "high normal" glucose levels and other metabolic syndrome components on arterial endothelial function and intima-media thickness in apparently healthy Chinese subjects: the CATHAY study. Arterioscler Thromb Vasc Biol 2004;24:739-743. [Free Full Text]
Kim DJ, Kim KW, Cho NH, Noh JH, Lee MS, Lee MK. The cutoff value of fasting plasma glucose to differentiate frequencies of cardiovascular risk factors in a Korean population. Diabetes Care 2003;26:3354-3356. [Free Full Text]
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497. [Free Full Text]
Rothman DL, Magnusson I, Katz LD, Shulman RG, Shulman GI. Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR. Science 1991;254:573-576. [Free Full Text]
Gastaldelli A, Miyazaki Y, Pettiti M, et al. Separate contribution of diabetes, total fat mass, and fat topography to glucose production, gluconeogenesis, and glycogenolysis. J Clin Endocrinol Metab 2004;89:3914-3921. [Free Full Text]
Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997;46:3-10. [Erratum, Diabetes 1997;46:536.] [Abstract]
Lam TK, Pocai A, Gutierrez-Juarez R, et al. Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis. Nat Med 2005;11:320-327. [CrossRef][Web of Science][Medline]
Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003;112:1785-1788. [CrossRef][Web of Science][Medline]
Muse ED, Obici S, Bhanot S, et al. Role of resistin in diet-induced hepatic insulin resistance. J Clin Invest 2004;114:232-239. [CrossRef][Web of Science][Medline]
Banerjee RR, Rangwala SM, Shapiro JS, et al. Regulation of fasted blood glucose by resistin. Science 2004;303:1195-1198. [Free Full Text]
Bajaj M, Suraamornkul S, Hardies LJ, Pratipanawatr T, DeFronzo RA. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes Relat Metab Disord 2004;28:783-789. [CrossRef][Web of Science][Medline]
Appendix
The following are members of the Israeli Diabetes Research GroupInvestigators, all in Israel: Soroka Medical Center, Beer-Sheva I. Harman-Bohem; Hillel Yaffe Medical Center, Hadera A. Jaffe; Rambam Medical Center, Haifa E. Karnieliand N. Shehadeh; Lin Medical Center, Haifa O. Minuchin;Wolfson Medical Center, Holon J. Wainstein; A. ClalitHealth Services, Jaffa E. Stern; HadassahHebrewUniversity Hospital, Jerusalem B. Glaser and I. Raz;Clalit Health Services, Jerusalem A. Tsur; Western GalileeHospital, Nahariya T.A. Herskovits; Sheba Medical Center,Tel-Hashomer O. Kalter-Leibovici; Kaplan Medical Center,Rehovot H. Knobler; Assaf Harofeh Medical Center, Zerifin A. Buchs and M. Rapoport; Maccabi Healthcare Services,Rishon-Le-Ziyon J. Cohen; Souraski Medical Center, Tel-Aviv A. Robinshtein; Clalit Health Services, Tel-Aviv Y. Yerushalmy.
Zhou, J., Li, H., Ran, X., Yang, W., Li, Q., Peng, Y., Li, Y., Gao, X., Luan, X., Wang, W., Jia, W.
(2009). Reference Values for Continuous Glucose Monitoring in Chinese Subjects. Diabetes Care
32: 1188-1193
[Abstract][Full Text]
The International Expert Committee,
(2009). International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabetes Care
32: 1327-1334
[Full Text]
Sheehy, A. M., Coursin, D. B., Gabbay, R. A.
(2009). Revisiting Screening for Type 2 Diabetes Mellitus: To Screen or Not to Screen, That Is the Question-Reply-I. Mayo Clin Proc.
84: 384-385
[Full Text]
Gao, L., Mann, G. E.
(2009). Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signalling. Cardiovasc Res
82: 9-20
[Abstract][Full Text]
Goth, L.
(2008). Catalase Deficiency and Type 2 Diabetes. Diabetes Care
31: e93-e93
[Full Text]
Lyssenko, V., Jonsson, A., Almgren, P., Pulizzi, N., Isomaa, B., Tuomi, T., Berglund, G., Altshuler, D., Nilsson, P., Groop, L.
(2008). Clinical Risk Factors, DNA Variants, and the Development of Type 2 Diabetes. NEJM
359: 2220-2232
[Abstract][Full Text]
Tirosh, A., Shai, I., Bitzur, R., Kochba, I., Tekes-Manova, D., Israeli, E., Shochat, T., Rudich, A.
(2008). Changes in Triglyceride Levels Over Time and Risk of Type 2 Diabetes in Young Men. Diabetes Care
31: 2032-2037
[Abstract][Full Text]
Perreault, L., Bergman, B. C., Playdon, M. C., Dalla Man, C., Cobelli, C., Eckel, R. H.
(2008). Impaired fasting glucose with or without impaired glucose tolerance: progressive or parallel states of prediabetes?. Am. J. Physiol. Endocrinol. Metab.
295: E428-E435
[Abstract][Full Text]
Genuth, S., Kahn, R.
(2008). A Step Backward--or Is it Forward?. Diabetes Care
31: 1093-1096
[Full Text]
Gupta, A. K., Dahlof, B., Dobson, J., Sever, P. S., Wedel, H., Poulter, N.R., on behalf of the Anglo-Scandinavian Cardiac Outcom,
(2008). Determinants of New-Onset Diabetes Among 19,257 Hypertensive Patients Randomized in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm and the Relative Influence of Antihypertensive Medication. Diabetes Care
31: 982-988
[Abstract][Full Text]
Fleischman, A., Shoelson, S. E., Bernier, R., Goldfine, A. B.
(2008). Salsalate Improves Glycemia and Inflammatory Parameters in Obese Young Adults. Diabetes Care
31: 289-294
[Abstract][Full Text]
Tomkin, G. H.
(2008). Targets for Intervention in Dyslipidemia in Diabetes. Diabetes Care
31: S241-S248
[Abstract][Full Text]
Pereg, D., Tirosh, A., Shochat, T., Hasdai, D., for the Metabolic, Lifestyle and Nutrition Assessm,
(2008). Mild renal dysfunction associated with incident coronary artery disease in young males. Eur Heart J
29: 198-203
[Abstract][Full Text]
Vasan, R. S.
(2008). What is an abnormal blood glucose level? Combining lessons from epidemiology and in vivo plaque imaging.. J Am Coll Cardiol Img
1: 46-48
[Full Text]
Hadler, N. M.
(2008). Oral Hypoglycemics and Diabetic Nephropathy. CJASN
3: 159-162
[Full Text]
Oberlinner, C., Neumann, S. M., Ott, M. G., Zober, A.
(2008). Screening for pre-diabetes and diabetes in the workplace. Occup Med (Lond)
58: 41-45
[Abstract][Full Text]
Gambino, R.
(2007). Glucose: A Simple Molecule That Is Not Simple to Quantify. Clin. Chem.
53: 2040-2041
[Full Text]
Tirosh, A., Rudich, A., Shochat, T., Tekes-Manova, D., Israeli, E., Henkin, Y., Kochba, I., Shai, I.
(2007). Changes in Triglyceride Levels and Risk for Coronary Heart Disease in Young Men. ANN INTERN MED
147: 377-385
[Abstract][Full Text]
Chiu, C.-J., Milton, R. C, Gensler, G., Taylor, A.
(2007). Association between dietary glycemic index and age-related macular degeneration in nondiabetic participants in the Age-Related Eye Disease Study. Am. J. Clin. Nutr.
86: 180-188
[Abstract][Full Text]
Bock, G., Dalla Man, C., Campioni, M., Chittilapilly, E., Basu, R., Toffolo, G., Cobelli, C., Rizza, R.
(2006). Pathogenesis of Pre-Diabetes: Mechanisms of Fasting and Postprandial Hyperglycemia in People With Impaired Fasting Glucose and/or Impaired Glucose Tolerance. Diabetes
55: 3536-3549
[Abstract][Full Text]
Yamazaki, H., Zawalich, K. C., Zawalich, W. S.
(2006). Desensitization of the pancreatic beta-cell: effects of sustained physiological hyperglycemia and potassium. Am. J. Physiol. Endocrinol. Metab.
291: H1381-H1387
[Abstract][Full Text]
Malnick, S.D.H., Knobler, H.
(2006). The medical complications of obesity. QJM
99: 565-579
[Full Text]
Carpentier, Y. A, Portois, L., Malaisse, W. J
(2006). n-3 Fatty acids and the metabolic syndrome. Am. J. Clin. Nutr.
83: S1499-1504S
[Abstract][Full Text]
Shaw, J. E., Zimmet, P. Z., Alberti, K. G. M.M.
(2006). Point: Impaired Fasting Glucose: The Case for the New American Diabetes Association Criterion. Diabetes Care
29: 1170-1172
[Full Text]
Rosenbloom, A. L.
(2006). Implications for Primary Care of Diabetes and Impaired Fasting Glucose Prevalence in Adolescents. Arch Pediatr Adolesc Med
160: 550-552
[Full Text]
Gambino, R., Reichberg, S., Schwartz, J. G., Tirosh, A., Shai, I., Rudich, A.
(2006). Normal Fasting Plasma Glucose Levels and Type 2 Diabetes. NEJM
354: 87-88
[Full Text]
(2005). High `Normal' Fasting Glucose Signals Diabetes Risk in Men. DOC News
2: 12-12
[Full Text]